KẾT QUẢ ĐIỀU TRỊ UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ KHÔNG ĐỘT BIẾN EGFR DI CĂN NÃO BẰNG TIA XẠ KẾT HỢP HÓA CHẤT PHÁC ĐỒ CÓ PLATINUM TẠI BỆNH VIỆN K

Abstract

Purpose: Our study aims to scrutinize clinical characteristics, assess treatment outcomes, and analyze factors related to survival rates. In Gamma knife radiotherapy and whole-brain radiotherapy for metastatic brain, without EGFR gene mutation in NSCLC patients at K Hospital. Methods: 120 NSCLC patients, without EGFR gene mutation, and brain metastases. Treatment: 60 patients with Gamma knife radiotherapy, 60 patients with whole-brain radiotherapy, sequentially combined with Platinum-based chemotherapy like Paclitaxel-Carboplatin or Pemetrexet-Cisplatin at K Hospital from 2018 to 2023. Observations of clinical characteristics, survival outcomes, and analysis of relevant factors. Results: Median OS for the whole-brain radiotherapy group was 6 ± 0.4 months. Median OS for Gamma knife combined with Platinum chemotherapy was 17 ± 2.9 months. Survival rates for Gamma knife-treated groups at 6 months: 89.9%, 12 months: 62.9%, 18 months: 42.3%. Median PFS at brain : 12 ± 1.7 months. Statistical significance observed in the number of metastatic lesions between OS, PFS in the brain (p < 0.05). Conclusion: Gamma knife radiotherapy combined with Platinum-based chemotherapy in NSCLC patients without EGFR mutation in brain metastases yields a superior OS result of 17 ± 2.9 months compared to the whole-brain radiotherapy group, which had a shorter OS time of 6 ± 0.4 months. The number of metastatic lesions shows statistical significance with both OS and PFS durations.